Possible causes of phenocopy syndrome in multiple endocrine neoplasia type 1
DOI: 10.32364/2587-6821-2024-8-9-4
D.A. Trukhina, E.O. Mamedova, Zh.E. Belaya, G.A. Melnichenko
National Medical Research Center for Endocrinology, Moscow, Russian Federation
Multiple endocrine neoplasia type 1 (MEN-1) is a rare autosomal dominant disorder resulting from mutations in the MEN1 gene, which codes for the menin protein. This syndrome is marked by the development of tumors in the parathyroid glands, gastroenteropancreatic neuroendocrine tumors, pituitary adenomas, alongside other endocrine and non-endocrine tumors. In 5–10% of individuals exhibiting symptoms of MEN-1, no mutations are detected in the MEN1 gene; this clinical picture is classified as phenocopy syndrome. In such instances, mutations may reside in unexamined regions of the MEN1 gene, or alternative gene silencing mechanisms and mutations in other related genes may contribute to MEN1-associated tumor pathogenesis. Identifying a genetically confirmed MEN-1 syndrome in patients manifesting MEN-1 symptoms is essential for evaluating tumor development risks and optimizing follow-up protocols. This is particularly important since patients with genetically confirmed MEN-1 syndrome generally face a reduced life expectancy compared to the broader population and experience a more aggressive disease progression than those with clinical manifestations of the syndrome without identifiable mutations.
Keywords: multiple endocrine neoplasia type 1, phenocopy, genetics, epigenetics.
For citation: Trukhina D.A., Mamedova E.O., Belaya Zh.E., Melnichenko G.A. Possible causes of phenocopy syndrome in multiple endocrine neoplasia type 1. Russian Medical Inquiry. 2024;8(9):526–530 (in Russ.). DOI: 10.32364/2587-6821-2024-8-9-4
About the authors:
Diana A. Trukhina — Assistant of the Methodological Accreditation and Simulation Center, National Medical Research Center for Endocrinology; 11, Dmitry Ulyanov str., Moscow, 117292, Russian Federation; ORCID iD 0000-0002-1359-8297
Elizaveta O. Mamedova — C. Sc. (Med.), Senior Researcher at the Department of Osteoporosis and Osteopathies, National Medical Research Center for Endocrinology; 11, Dmitry Ulyanov str., Moscow, 117292, Russian Federation; ORCID iD 0000-0002-9783-3599
Zhanna E. Belaya — Dr. Sc. (Med.), Professor, Head of the Department of Osteoporosis and Osteopathies, National Medical Research Center for Endocrinology; 11, Dmitry Ulyanov str., Moscow, 117292, Russian Federation; ORCID iD 0000-0002-6674-6441
Galina A. Melnichenko — Academician of the Russian Academy of Sciences, Dr. Sc. (Мed.), Professor, Deputy Director for Scientific Work, National Medical Research Center for Endocrinology; 11, Dmitry Ulyanov str., Moscow, 117292, Russian Federation; ORCID iD 0000-0002-5634-7877
Contact information: Diana A. Trukhina, e-mail: truhina.diana@endocrincentr.ru
Financial Disclosure: the research was supported by the the grant of the Russian Science Foundation No. 24-15-00283.
There is no conflict of interest.
Received 12.08.2024.
Revised 04.09.2024.
Accepted 27.09.2024.
2. Al-Salameh A., Cadiot G., Calender A. et al. Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol. 2021;17(4):207–224. DOI: 10.1038/s41574-021-00468-3
3. Brandi M.L., Agarwal S.K., Perrier N.D. et al. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev. 2021;42(2):133–170. DOI: 10.1210/endrev/bnaa031
4. Thakker R.V., Newey P.J., Walls G.V. et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011. DOI: 10.1210/jc.2012-1230
5. Pieterman C.R.C., Valk G.D. Update on the clinical management of multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf). 2022;97(4):409–423. DOI: 10.1111/cen.14727
6. Pieterman C.R.C., van Leeuwaarde R.S., van den Broek M.F.M. et al. Multiple Endocrine Neoplasia Type 1. South Dartmouth (MA): MDText.com, Inc.; 2000.
7. Kamilaris C.D.C., Stratakis C.A. Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis. Front Endocrinol (Lausanne). 2019;10:339. DOI: 10.3389/fendo.2019.00339
8. Mele C., Mencarelli M., Caputo M. et al. Phenotypes Associated With MEN1 Syndrome: A Focus on Genotype-Phenotype Correlations. Front Endocrinol (Lausanne). 2020;11:591501. DOI: 10.3389/fendo.2020.591501
9. Giusti F., Cianferotti L., Boaretto F. et al. Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine. 2017;58(2):349–359. DOI: 10.1007/s12020-017-1234-4
10. Kövesdi A., Tóth M., Butz H. et al. True MEN1 or phenocopy? Evidence for geno-phenotypic correlations in MEN1 syndrome. Endocrine. 2019;65(2):451–459. DOI: 10.1007/s12020-019-01932-x
11. Pieterman C.R.C., Hyde S.M., Wu S.Y. et al. Understanding the clinical course of genotype-negative MEN1 patients can inform management strategies. Surgery. 2021;169(1):175–184. DOI: 10.1016/j.surg.2020.04.067
12. De Laat J.M., van der Luijt R.B., Pieterman C.R. et al. MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. BMC Med. 2016;14(1):182. DOI: 10.1186/s12916-016-0708-1
13. Agarwal S.K., Mateo C.M., Marx S.J. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab. 2009;94(5):1826–1834. DOI: 10.1210/jc.2008-2083
14. Van den Broek M.F.M., van Nesselrooij B.P.M., Verrijn Stuart A.A. et al. Clinical Relevance of Genetic Analysis in Patients With Pituitary Adenomas: A Systematic Review. Front Endocrinol (Lausanne). 2019;10:837. DOI: 10.3389/fendo.2019.00837
15. Pardi E., Borsari S., Saponaro F. et al. Mutational and large deletion study of genes implicated in hereditary forms of primary hyperparathyroidism and correlation with clinical features. PLoS One. 2017;12(10):e0186485. DOI: 10.1371/journal.pone.0186485
16. Backman S., Bajic D., Crona J. et al. Whole genome sequencing of apparently mutation-negative MEN1 patients. Eur J Endocrinol. 2020;182(1):35–45. DOI: 10.1530/EJE-19-0522
17. Lines K.E., Nachtigall L.B., Dichtel L.E. et al. Multiple Endocrine Neoplasia Type 1 (MEN1) Phenocopy Due to a Cell Cycle Division 73 (CDC73) Variant. J Endocr Soc. 2020;4(11):bvaa142. DOI: 10.1210/jendso/bvaa142
18. Hannan F.M., Kallay E., Chang W. et al. The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat Rev Endocrinol. 2018;15(1):33–51. DOI: 10.1038/s41574-018-0115-0
19. Ozawa A., Agarwal S.K., Mateo C.M. et al. The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. J Clin Endocrinol Metab. 2007;92(5):1948–1951. DOI: 10.1210/jc.2006-2563
20. Chevalier B., Coppin L., Romanet P. et al. Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature Review. J Clin Endocrinol Metab. 2024;109(7):e1482–e1493. DOI: 10.1210/clinem/dgae055
21. Frederiksen A., Rossing M., Hermann P. et al. Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases. J Clin Endocrinol Metab. 2019;104(9):3637–3646. DOI: 10.1210/jc.2019-000
22. Belar O., De La Hoz C., Pérez-Nanclares G. et al. Novel mutations in MEN1, CDKN1B and AIP genes in patients with multiple endocrine neoplasia type 1 syndrome in Spain. Clin Endocrinol (Oxf). 2012;76(5):719–724. DOI: 10.1111/j.1365-2265.2011.04269.x
23. Newey P.J. Hereditary Primary Hyperparathyroidism. Endocrinol Metab Clin North Am. 2021;50(4):663–681. DOI: 10.1016/j.ecl.2021.08.003
24. Turner J.J., Christie P.T., Pearce S.H. et al. Diagnostic challenges due to phenocopies: lessons from Multiple Endocrine Neoplasia type1 (MEN1). Hum Mutat. 2010;31(1):E1089–E1101. DOI: 10.1002/humu.21170
25. Мамедова Е.О., Лисина Д.В., Белая Ж.Е. Редкие формы наследственных новообразований эндокринной системы: аденома гипофиза в сочетании с феохромоцитомой и/или параганглиомой. Проблемы Эндокринологии. 2023;69(2):24–30. DOI: 10.14341/probl13196Mamedova E.O., Lisina D.V., Belaya Zh.E. Rare forms of hereditary endocrine neoplasia: co-existence of pituitary adenoma and pheochromocytoma/paraganglioma. Problems of Endocrinology. 2023;69(2):24–30 (in Russ.). DOI: 10.14341/probl13196
26. Seabrook A.J., Harris J.E., Velosa S.B. et al. Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5?. J Clin Endocrinol Metab. 2021;106(4):1163–1182. DOI: 10.1210/clinem/dgaa957
27. Kooblall K.G., Boon H., Cranston T. et al. Multiple Endocrine Neoplasia Type 1 (MEN1) 5'UTR Deletion, in MEN1 Family, Decreases Menin Expression. J Bone Miner Res. 2021;36(1):100–109. DOI: 10.1002/jbmr.4156
28. Carvalho R.A., Urtremari B., Jorge A.A.L. et al. Germline mutation landscape of multiple endocrine neoplasia type 1 using full gene next-generation sequencing. Eur J Endocrinol. 2018;179(6):391–407. DOI: 10.1530/EJE-18-0430
29. Zhao Y.X., Wang O., Song A. et al. The risk of concurrent malignancies in patients with multiple endocrine neoplasia type 1: insights into clinical characteristics of those with multiple endocrine neoplasia type 1. J Endocrinol Invest. 2024;47(8):1931–1939. DOI: 10.1007/s40618-023
30. De Laat J.M., van Leeuwaarde R.S., Valk G.D. The Importance of an Early and Accurate MEN1 Diagnosis. Front Endocrinol (Lausanne). 2018;9:533. DOI: 10.3389/fendo.2018.00533
31. Kremer L.S., Bader D.M., Mertes C. et al. Genetic diagnosis of Mendelian disorders via RNA sequencing. Nat Commun. 2017;8:15824. DOI: 10.1038/ncomms15824
32. Lagarde A., Le Collen L., Boulagnon C. et al. Early Detection of Relapse by ctDNA Sequencing in a Patient with Metastatic Thymic Tumor and MEN1 Mosaicism. J Clin Endocrinol Metab. 2022;107(10):e4154–e4158. DOI: 10.1210/clinem/dgac454
33. English K.A., Thakker R.V., Lines K.E. The role of DNA methylation in human pancreatic neuroendocrine tumours. Endocr Oncol. 2023;3(1):e230003. DOI: 10.1530/EO-23-0003
34. Lin W., Watanabe H., Peng S. et al. Dynamic epigenetic regulation by menin during pancreatic islet tumor formation. Mol Cancer Res. 2015;13(4):689–698. DOI: 10.1158/1541-7786.MCR-14-0457
35. Feng Z., Ma J., Hua X. Epigenetic regulation by the menin pathway. Endocr Relat Cancer. 2017;24(10):T147–T159. DOI: 10.1530/ERC-17-0298
36. Coyle K.M., Boudreau J.E., Marcato P. Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine. Biomed Res Int. 2017;2017:9620870. DOI: 10.1155/2017/9620870
37. Tan T., Shi P., Abbas M.N. et al. Epigenetic modification regulates tumor progression and metastasis through EMT (Review). Int J Oncol. 2022;60(6):70. DOI: 10.3892/ijo.2022.5360
38. De Paoli-Iseppi R., Prentice L., Marthick J.R. et al. Multiple endocrine neoplasia type 1: clinical correlates of MEN1 gene methylation. Pathology. 2018;50(6):622–628. DOI: 10.1016/j.pathol.2018.05.006
39. Wang L.H., Wu C.F., Rajasekaran N., Shin Y.K. Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview. Cell Physiol Biochem. 2018;51(6):2647–2693. DOI: 10.1159/000495956
40. Butz H. Circulating Noncoding RNAs in Pituitary Neuroendocrine Tumors-Two Sides of the Same Coin. Int J Mol Sci. 2022;23(9):5122. DOI: 10.3390/ijms23095122
41. O'Brien J., Hayder H., Zayed Y., Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne). 2018;9:402. DOI: 10.3389/fendo.2018.00402
42. Luzi E., Marini F., Giusti F. et al. The negative feedback-loop between the oncomir Mir-24-1 and menin modulates the Men1 tumorigenesis by mimicking the "Knudson's second hit". PLoS One. 2012;7(6):e39767. DOI: 10.1371/journal.pone.003
43. Vijayaraghavan J., Maggi E.C., Crabtree J.S. miR-24 regulates menin in the endocrine pancreas. Am J Physiol Endocrinol Metab. 2014;307(1):E84–E92. DOI: 10.1152/ajpendo.00542.2013
44. Luzi E., Ciuffi S., Marini F. et al. Analysis of differentially expressed microRNAs in MEN1 parathyroid adenomas. Am J Transl Res. 2017;9(4):1743–1753.
45. Hai N., Aoki N., Shimatsu A. et al. Clinical features of multiple endocrine neoplasia type 1 (MEN1) phenocopy without germline MEN1 gene mutations: analysis of 20 Japanese sporadic cases with MEN1. Clin Endocrinol (Oxf). 2000;52(4):509–518. DOI: 10.1046/j.1365-2265.2000.00966.x
46. Yeh M.W., Ituarte P.H., Zhou H.C. et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab. 2013;98(3):1122–1129. DOI: 10.1210/jc.2012-4022
47. Minisola S., Arnold A., Belaya Z. et al. Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism. J Bone Miner Res. 2022;37(11):2315–2329. DOI: 10.1002/jbmr.4665
48. Scangas G.A., Laws E.R.Jr. Pituitary incidentalomas. Pituitary. 2014;17(5):486–491. DOI: 10.1007/s11102-013-0517-x
49. Daly A.F., Tichomirowa M.A., Beckers A. The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2009;23(5):543–554. DOI: 10.1016/j.beem.2009.05.008
50. Petrossians P., Daly A.F., Natchev E. et al. Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. Endocr Relat Cancer. 2017;24(10):505–518. DOI: 10.1530/ERC-17-0253
51. Nachtigall L.B., Guarda F.J., Lines K.E. et al. Clinical MEN-1 Among a Large Cohort of Patients With Acromegaly. J Clin Endocrinol Metab. 2020;105(6):e2271–e2281. DOI: 10.1210/clinem/dgaa142
This work is licensed under a Creative Commons «Attribution» 4.0 License.
